Rabigen SAG2

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

live attenuated rabies virus, SAG2 strain

Available from:

Virbac S.A.

ATC code:

QI07AA02

INN (International Name):

live vaccine against rabies

Therapeutic group:

Raccoon dogs (Nyctereutes procyonoides); Red foxes (Vulpes vulpes)

Therapeutic area:

Live viral vaccines

Therapeutic indications:

For the active immunisation of red foxes and raccoon dogs to prevent infection by rabies virus.The duration of protection is of at least 6 months.

Product summary:

Revision: 9

Authorization status:

Authorised

Authorization date:

2000-04-06

Patient Information leaflet

                                11
-
20 baits per square km over the areas where fox / raccoon dog density
indexes were more than 3
foxes / raccoon dogs seen per 10 km.
Read the package leaflet before use.
8.
SPECIAL WARNINGS, IF NECESSARY
It is recommended to wear rubber gloves.
People handling and distributing this vaccine should be vaccinated
against rabies.
Immunocompromised/immunosuppressed individuals must not be allowed to
handle this vaccine.
In the event of human exposure to the active ingredient of the
vaccine, seek medical advice
immediately and show the package leaflet i or the label to the
physician.
No adverse events have been reported in the target species.
As this vaccine presentation contains traces of gentamicin and
contains tetracycline as biomarker,
occasional hypersensitivity reactions may be observed in domestic
animals that have accidentally
ingested the bait.
Vomiting due to gastric intolerance (potentially due to the
aluminium/PVC sachet as part of the bait
vaccine), in dogs which have accidentally ingested the bait, has been
reported.
9.
EXPIRY DATE
EXP : {month/year}
10.
SPECIAL STORAGE CONDITIONS
Store in a freezer at -40°C to -20°C.
Protect from light. Keep the boxes tightly closed.
11.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
WASTE MATERIALS, IF ANY
Dispose of waste material and any unplaced baits at the end of the day
of distribution by boiling or
incineration or immersion in an appropriate disinfectant approved for
use by the competent authorities.
12.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
For animal treatment only - to be supplied only on veterinary
prescription.
Restricted to duly designated competent administrative authorities.
The import, sale, supply and/or use of this veterinary medicinal
product is or may be prohibited in
certain
Member
States
on
the
whole
or
part
of
their
territory,
see
package
insert
for
further
information.
13.
THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach a
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabigen SAG2 oral suspension, for red foxes and raccoon dogs.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE :
Live attenuated rabies virus, SAG2 strain
minimum 8 log10 CCID50*/dose
* CCID50 : Cell Culture Infective Dose 50%
EXCIPIENTS :
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Red foxes (_Vulpes vulpes_) and raccoon dogs (_Nyctereutes
procyonoides_).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of red foxes and raccoon dogs to prevent
infection by rabies virus.
The duration of protection is of at least 6 months.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Not applicable.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Baits shall not be distributed in inhabited areas, roads and watery
areas.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO
ANIMALS
It is recommended to wear rubber gloves.
People handling and distributing this vaccine should be vaccinated
against rabies.
Immunocompromised/immunosuppressed individuals must not be allowed to
handle this vaccine.
In the event of human exposure to the active ingredient of the
vaccine, seek medical advice
immediately and show the package leaflet or the label to the
physician.
3
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
No adverse events have been reported in the target species.
As this vaccine presentation contains traces of gentamicin and
contains tetracycline as biomarker,
occasional hypersensitivity reactions may be observed in domestic
animals that have accidentally
ingested the bait.
Vomiting due to gastric intolerance (potentially due to the
aluminium/PVC sachet as part of the bait
vaccine), in dogs which have accidentally ingested the bait, has been
reported.
4.7
USE DURING PREGNANCY, LACTATION OR LAY
The safety of the vaccine in
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 06-11-2018
Public Assessment Report Public Assessment Report Bulgarian 21-07-2013
Patient Information leaflet Patient Information leaflet Spanish 06-11-2018
Public Assessment Report Public Assessment Report Spanish 21-07-2013
Patient Information leaflet Patient Information leaflet Czech 06-11-2018
Public Assessment Report Public Assessment Report Czech 21-07-2013
Patient Information leaflet Patient Information leaflet Danish 06-11-2018
Public Assessment Report Public Assessment Report Danish 21-07-2013
Patient Information leaflet Patient Information leaflet German 06-11-2018
Public Assessment Report Public Assessment Report German 21-07-2013
Patient Information leaflet Patient Information leaflet Estonian 06-11-2018
Public Assessment Report Public Assessment Report Estonian 21-07-2013
Patient Information leaflet Patient Information leaflet Greek 06-11-2018
Public Assessment Report Public Assessment Report Greek 21-07-2013
Patient Information leaflet Patient Information leaflet French 06-11-2018
Public Assessment Report Public Assessment Report French 21-07-2013
Patient Information leaflet Patient Information leaflet Italian 06-11-2018
Public Assessment Report Public Assessment Report Italian 21-07-2013
Patient Information leaflet Patient Information leaflet Latvian 06-11-2018
Public Assessment Report Public Assessment Report Latvian 21-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 06-11-2018
Public Assessment Report Public Assessment Report Lithuanian 21-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 06-11-2018
Public Assessment Report Public Assessment Report Hungarian 21-07-2013
Patient Information leaflet Patient Information leaflet Maltese 06-11-2018
Public Assessment Report Public Assessment Report Maltese 21-07-2013
Patient Information leaflet Patient Information leaflet Dutch 06-11-2018
Public Assessment Report Public Assessment Report Dutch 21-07-2013
Patient Information leaflet Patient Information leaflet Polish 06-11-2018
Public Assessment Report Public Assessment Report Polish 21-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 06-11-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 06-11-2018
Public Assessment Report Public Assessment Report Portuguese 21-07-2013
Patient Information leaflet Patient Information leaflet Romanian 06-11-2018
Public Assessment Report Public Assessment Report Romanian 21-07-2013
Patient Information leaflet Patient Information leaflet Slovak 06-11-2018
Public Assessment Report Public Assessment Report Slovak 21-07-2013
Patient Information leaflet Patient Information leaflet Slovenian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 06-11-2018
Public Assessment Report Public Assessment Report Slovenian 21-07-2013
Patient Information leaflet Patient Information leaflet Finnish 06-11-2018
Public Assessment Report Public Assessment Report Finnish 21-07-2013
Patient Information leaflet Patient Information leaflet Swedish 06-11-2018
Public Assessment Report Public Assessment Report Swedish 21-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 06-11-2018
Patient Information leaflet Patient Information leaflet Icelandic 06-11-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 06-11-2018
Patient Information leaflet Patient Information leaflet Croatian 06-11-2018

View documents history